Steve Braunstein, M.D., Ph.D.
Dr. Steve Braunstein is a radiation oncologist with a clinical interest in the treatment of central nervous system, pediatric, thoracic, and soft tissue malignancies. He has expertise in modern radiation therapy techniques including stereotactic radiotherapy, intraoperative radiotherapy, and intensity modulated radiation therapy.
Dr. Braunstein earned his M.D. at New York University School of Medicine where he also obtained a Ph.D. studying essential molecular pathways by which cancer cells mediate response to radiation. Throughout his radiation oncology residency at UCSF, he has continued such work to further resolve genetic polymorphisms which yield the observed heterogeneity of tumor cell population radiosensitivity and risk of radiation-related secondary cancers. He continues to expand his work in current translational research efforts towards intensifying the tumor response while minimizing treatment-related toxicity for patients undergoing radiation therapy as part of modern multimodal cancer treatment.
|2009||New York University School of Medicine, New York||MD/PhD|
|2010||Brigham and Women's Hospital, Boston, MA||Internship||Internal Medicine|
|2010-2014||University of California San Francisco, San Francisco, CA||Resident||Radiation Therapy|
|2013||University of California San Francisco, San Francisco, CA||Chief Resident||Radiation Therapy|
|2014-present||UCSF||Assistant Professor in Residence||Radiation Oncology|
Awards & Honors
|1996||Presidential Full Tuition College Scholarship|
|1997||Phi Beta Kappa Inductee|
|1997||HHMI Undergraduate Student Research Fellowship|
|1998||CUNY Jonas Salk Medical Scholarship|
|2003||NYC Urban Health Initiative Grant|
|2008||Honors in Doctoral Dissertation|
|2012||UCSF Patient Care Fund Grant|
|2013||UCSF Resident QI Champion|
|2013||UCSF Exceptional Physician Award|
|2014||Mount Zion Health Fund Research Award|
|2014||UCSF Patient Care Fund Grant|
Braunstein S, Dioniso S, Lometti M, Pinnaduwage D, Chuang C, Yom S, Gottschalk A, Descovich, M. Evaluation of Ray Tracing and Monte Carlo algorithms in dose calculation and clinical outcomes for robotic stereotactic body radiotherapy of lung cancers. JSBRT 2014;3(1):67-79.
Braunstein S, Nakamura JL. Radiotherapy-induced malignancies: Review of clinical features, pathobiology and evolving approaches for mitigating risk. Front Oncol 2013 Apr;3:73. PMID 23565507.
Nie K, Chuang C, Kirby N, Braunstein S, Pouliot J. Site-Specific Deformable Imaging Registration (DIR) Algorithm Selection Using Patient-Based Simulated Deformations. Med Phys 2013 Apr; 40(4). PMID 23556905.
Choi G, Huang B, Pinarbasi E, Braunstein S, Horvai A, Kogan S, Bhatia S, Faddegon B, Nakamura JL. Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumor modeling second malignant neoplasms.Cancer Res 2012 Dec;72(24):5425-34. PMID 23071067.
Badura M, Braunstein S, Zavadil J, Schneider RJ. DNA damage and eIF4GI in breast cancer cells reprogram translation for survival and DNA repair mRNAs. PNAS. 2012 Nov;109(46):18767-72. PMID 23112151.
Ramirez-Valle F, Badura ML, Braunstein S, Narasimhan M, Schneider RJ.Mitotic raptor promotes mTORC1 activity, G(2)/M cell cycle progression, and internal ribosome entry site-mediated mRNA translation. Mol Cell Biol. 2010 Jul;30(13):3151-64. PMID: 20439490.
Braunstein S, Badura ML, Xi Q, Formenti SC, Schneider RJ. Regulation of protein synthesis by ionizing radiation. Mol Cell Biol. 2009 Nov; 29(21):5645-5656. Cited in Pubmed; PMID: 19704005
Matsumura S, Wang B, Kawashima N, Braunstein S, Badura M, Cameron TO, Babb JS, Schneider RJ, Formenti SC, Dustin ML, Demaria S. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol. 2008 Sep; 181(5): 3099-3107. PMID: 18713980.
Ramírez-Valle F, Braunstein S, Zavadil J, Formenti SC, Schneider RJ. eIF4GI links nutrient sensing by mTOR to cell proliferation and inhibition of autophagy. J Cell Biol. 2008 Apr; 181(2): 293-307. PMID: 18426977.
Braunstein S, Formenti SC, Schneider RJ. Acquisition of stable inducible up-regulation of nuclear factor-kappaB by tumor necrosis factor exposure confers increased radiation resistance without increased transformation in breast cancer cells. Mol Cancer Res. 2008 Jan; 6(1): 78-88. PMID: 18234964.